ABSTRACT
Introduction Cognitive behavioral therapy for insomnia (CBT-I) is effective at treating chronic insomnia, yet in-person CBT-I can often be challenging to access. Prior studies have used technology to bridge barriers but have been unable to extensively assess the impact of the digital therapeutic on real-world patient experience and multi-dimensional outcomes. Among patients with insomnia, our aim is to determine the impact of a Prescription Digital Therapeutic (PDT) (PEAR-003b, FDA-authorized as Somryst; herein called PDT) that provides mobile-delivered CBT-I on patient-reported outcomes (PROs) and healthcare utilization.
Methods and Analysis We are conducting a pragmatically designed, prospective, multi-center randomized controlled trial that leverages Hugo, a unique patient-centered health data-aggregating platform for data collection and patient follow-up from Hugo Health. A total of 100 participants with insomnia from two health centers will be enrolled onto the Hugo Health platform, provided with a linked Fitbit (Inspire 2) to track activity, and then randomized 1:1 to receive (or not) the PDT for mobile-delivered CBT-I (Somryst). The primary outcome is a change in the insomnia severity index score (ISI) score from baseline to 9-weeks post-randomization. Secondary outcomes include healthcare utilization, health utility scores, and clinical outcomes; change in sleep outcomes as measured with sleep diaries; and a change in individual PROs including depressive symptoms, daytime sleepiness, health status, stress, and anxiety. For those allocated to the PDT, we will also assess engagement with the PDT.
Ethics and Dissemination The Institutional Review Boards at Yale University and the Mayo Clinic have approved the trial protocol. This trial will provide important data to patients, clinicians, and policymakers about the impact of the PDT device delivering CBT-I on PROs, clinical outcomes, and healthcare utilization. Findings will be disseminated to participants, presented at professional meetings, and published in peer-reviewed journals.
Trial Registration Number NCT04909229
Strengths and limitations of this study
This is the first controlled study to examine the impact of a mobile-delivered, prescription digital therapeutic (PDT) delivering Cognitive Behavioral Therapy for Chronic Insomnia (i.e., PEAR-003b, FDA-authorized as Somryst) on real-world patients outcomes of care that includes a multi-dimensional analysis of patient benefit across guideline-recommended health domains (e.g., insomnia severity index) and healthcare utilization (e.g., emergency department visits).
This randomized clinical trial will use Hugo, a novel patient-centered health data-aggregating platform for data collection and patient follow-up, which gathers and collates patient-reported outcomes, clinical outcomes, and healthcare utilization metrics for real-world patients with chronic insomnia. The participant has ownership over their data and contributes it to research.
Future studies should focus on patients with chronic insomnia as well as co-morbid conditions such as major depression and whether sleep improvements can be sustained, particularly in the long-term.
Competing Interest Statement
Dr. Dreyer reports research funding from the American Heart Association, the Canadian Institutes of Health Research and from the Medical Device Innovation Consortium (MDIC) as part of the National Evaluation System for health Technology Coordinating Center (NESTcc), Food and Drug Administration (FDA). Dr. Ross received research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the FDA to establish the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), MDIC as part of the NESTcc, AHRQ(R01HS022882), NHLBI of the NIH (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. Dr Shah is currently employed by Delta Airlines; when he was employed by the Mayo Clinic, Dr. Shah reported receiving research support through Mayo Clinic from the Food and Drug Administration, the Centers of Medicare & Medicaid Innovation under the Transforming Clinical Practice Initiative, the Agency for Healthcare Research and Quality (grants R01HS025164, R01HS025402, R03HS025517, and K12HS026379), the National Heart, Lung and Blood Institute of the National Institutes of Health (grants R56HL130496, R01HL131535, and R01HL151662), the National Science Foundation, the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology, and the Patient-Centered Outcomes Research Institute to develop a Clinical Data Research Network. Dr. Thorndike is an employee of Pear Therapeutics, that develops and distributes prescription digital therapeutics for health concerns and disease. Other authors report no other conflicts of interest.
Clinical Trial
NCT04909229
Funding Statement
This work was supported by the Medical Device Innovation Consortium (MDIC) on behalf of the National Evaluation System for health Technology (NEST) Coordinating Center (6292-2019-R2TC-B18), initiative funded by the U.S. Food and Drug Administration (FDA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views nor the endorsements of the Department of Health and Human Services or the FDA. While MDIC provided feedback on project conception and design, the organization will play no role in collection, management, analysis and interpretation of the data, nor preparation, review and approval of the manuscript. The research team, not the funder, made the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Yale University and the Mayo Clinic gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
apb1128{at}gmail.com
henry.yaggi{at}yale.edu
lynelle.schneeberg{at}yale.edu
ndshah{at}gmail.com
emanuel.lindsay{at}mayo.edu
kolla.bhanuprakash{at}mayo.edu
Jeffery.Molly{at}mayo.edu
mark.deeg{at}cullgen.com
kervin{at}mdic.org
frances.thorndike{at}peartherapeutics.com
joseph.ross{at}yale.edu
↵* The work conducted in this paper was completed while at Pear Therapeutics
Data Availability
All data produced in the present work are contained in the manuscript.